Madrigal制药 MDGL 深 沪
已收盘 09-12 16:00:00 美东时间
432.22
-7.230
-1.65%
华盛通- 最 高440.90
- 今 开439.99
- 成交量 19.06万股
- 最 低 426.17
- 昨 收 439.45
- 总市值 96.34亿
- 52周最高 457.16
- 市盈率 静 --
- 换手率 0.86%
- 52周最低 200.63
- 委 比 -86.92%
- 总股本 2228.90万
- 历史最高 457.16
- 量 比 0.54
- 振 幅 3.35%
- 历史最低 5.25
- 每 手 1
- 风险率 51.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $526
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $428 to $526.
09-12 20:56
Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
<p>Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced its participation in the Morgan Stanley 23<sup>rd</sup> Annual Global Health Care Conference on Sept. 8, 2025. The presentation will be live webcast and available for replay. Madrigal focuses on developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), with its approved medication, Rezdiffra, targeting MASH with moderate to advanced fibrosis. An ongoing Phase 3 ...
09-03 12:00
如何理解Fibroscan近期相关变化中长期重大意义？【创新药大牛市】分支思路(三)中小市值科技革命【国盛医药】【第411期】
（来源：国医盛视） 一、医药核心观点 当周（8.25-8.29）回顾与周专题： 当周（8.25-8.29）申万医药指数环比-0.65...
08-30 22:18
MASH drug developers rise as FDA accepts lenient trial requirement
Drug developers with products targeting a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Wednesday after the U.S. FDA said it has accepted an easy-to-m...
08-28 01:44
Inventiva surges as Piper Sandler issues bullish view citing lead asset
Inventiva (NASDAQ:IVA) climbed ~15% on Wednesday after Piper Sandler launched its coverage with an Overweight recommendation, citing the French biotech’s lead candidate, lanifibranor, targeted at the ...
08-27 23:52
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Providing a diverse range of perspectives from bullish to bearish, 4 analysts h...
08-26 20:00
JMP Securities Maintains Market Outperform on Madrigal Pharmaceuticals, Raises Price Target to $485
JMP Securities analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and raises the price target from $483 to $485.
08-20 19:54
6家中国药企进入全球TOP50！云南白药、中生、华东、百济、恒瑞、石药
作者 | 晓琳 编辑 | 郑瑶 国内药企上榜数量创历史新高，云南白药、中国生物、华东医药、百济神州、恒瑞医药、石药集团。 01 全球制药企业50强 中国6家药...
08-20 18:53
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth.
08-18 18:16
